More to come: humoral immune responses in MS

J Neuroimmunol. 2011 Dec 15:240-241:13-21. doi: 10.1016/j.jneuroim.2011.09.009. Epub 2011 Oct 21.

Abstract

Interest in the role of B-cells in multiple sclerosis (MS) pathogenesis has increased, and a number of B-cell targeted therapies are currently in clinical trials. B-cells are key mediators of the humoral immune response, with roles including antibody production and acting as antigen presenting cells. Whilst previously, the presence of B-cells within MS plaques has been thought to be secondary to T-cell dysregulation, it is now becoming clear that B-cells play an independent role in disease. In this review we will discuss the potential role of B-cells in MS, how this influences our understanding of the disease, and potential therapeutic implications.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • B-Lymphocytes / immunology*
  • B-Lymphocytes / pathology
  • Clinical Trials, Phase II as Topic / trends
  • Humans
  • Immunity, Humoral* / immunology
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / pathology
  • Multiple Sclerosis / therapy
  • Rituximab

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab